Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00540878 · ClinicalTrials.gov registry record · Phase 1
A Study to Estimate the Effect of Formulation on the Relative Absorption of SB-751689 Administered to Healthy Women
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00540878 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 25 participants.
The verdict
NCT00540878, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This study will examine the effects of formulation on the relative bioavailability of SB-751689 (400 mg) administered to healthy postmenopausal women. Subjects will receive a single oral dose of each formulation, with five formulations of SB-751689 tested in total. Blood samples will be taken up to 24 hours postdose after each dose administration. This study will provide information for future possible formulation development of SB-751689 for Phase III.
Interventions
- DRUG SB-751689 oral tablets (400 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2007-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00540878
The ClinicalTrials.gov registry entry for NCT00540878 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SB-751689 oral tablets (400 mg) is the first listed.
NCT00540878 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00540878 about?
NCT00540878 is a clinical study titled "A Study to Estimate the Effect of Formulation on the Relative Absorption of SB-751689 Administered to Healthy Women". This study will examine the effects of formulation on the relative bioavailability of SB-751689 (400 mg) administered to healthy postmenopausal women. Subjects will receive a single oral dose of each formulation, with five formulations of SB-751689 tested in total. Blood samples will be taken up to ...
What is the current status of trial NCT00540878?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2007-04.
What interventions are being tested in trial NCT00540878?
The interventions under investigation include: SB-751689 oral tablets (400 mg) (DRUG).
Who is sponsoring clinical trial NCT00540878?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.